Interestingly, in the latter group of patients, the outcome was directly correlated to the baseline levels of IL17/A, an inflammatory cytokine able to amplify and empower the cytotoxic effects of pre-existing CTLs in CRC tumor sites [26]. This evidence concerns the gene IL17A and neoplasm.